327 related articles for article (PubMed ID: 26297673)
41. COPD and stroke: are systemic inflammation and oxidative stress the missing links?
Austin V; Crack PJ; Bozinovski S; Miller AA; Vlahos R
Clin Sci (Lond); 2016 Jul; 130(13):1039-50. PubMed ID: 27215677
[TBL] [Abstract][Full Text] [Related]
42. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease.
Onishi K
J Cardiol; 2017 Aug; 70(2):128-134. PubMed ID: 28325523
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular risk in chronic obstructive pulmonary disease.
Maclay JD; McAllister DA; Macnee W
Respirology; 2007 Sep; 12(5):634-41. PubMed ID: 17875049
[TBL] [Abstract][Full Text] [Related]
44. Oxidants and COPD.
MacNee W
Curr Drug Targets Inflamm Allergy; 2005 Dec; 4(6):627-41. PubMed ID: 17305519
[TBL] [Abstract][Full Text] [Related]
45. Systemic manifestations of COPD.
Nussbaumer-Ochsner Y; Rabe KF
Chest; 2011 Jan; 139(1):165-73. PubMed ID: 21208876
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic potential of Panax ginseng and ginsenosides in the treatment of chronic obstructive pulmonary disease.
Shergis JL; Di YM; Zhang AL; Vlahos R; Helliwell R; Ye JM; Xue CC
Complement Ther Med; 2014 Oct; 22(5):944-53. PubMed ID: 25440386
[TBL] [Abstract][Full Text] [Related]
47. Chronic obstructive pulmonary disease and its comorbidities.
Panetta NL; Krachman S; Chatila WM
Panminerva Med; 2009 Jun; 51(2):115-23. PubMed ID: 19776712
[TBL] [Abstract][Full Text] [Related]
48. Astaxanthin: a novel potential treatment for oxidative stress and inflammation in cardiovascular disease.
Pashkow FJ; Watumull DG; Campbell CL
Am J Cardiol; 2008 May; 101(10A):58D-68D. PubMed ID: 18474276
[TBL] [Abstract][Full Text] [Related]
49. Aerobic capacity, oxidant stress, and chronic obstructive pulmonary disease--a new take on an old hypothesis.
Stevenson CS; Koch LG; Britton SL
Pharmacol Ther; 2006 Apr; 110(1):71-82. PubMed ID: 16343638
[TBL] [Abstract][Full Text] [Related]
50. Comorbidities and their impact on chronic obstructive pulmonary disease.
Dursunoğlu N; Köktürk N; Baha A; Bilge AK; Börekçi Ş; Çiftçi F; Gezmen Karadağ M; Çalık Kütükçü E; Noyan A; Polatlı M; Önen ZP; Sarınç S; Umut S; Uzaslan E; Kubat Üzüm A; Akkoca Yıldız Ö;
Tuberk Toraks; 2016 Dec; 64(4):289-298. PubMed ID: 28393718
[TBL] [Abstract][Full Text] [Related]
51. A self-management approach using self-initiated action plans for symptoms with ongoing nurse support in patients with Chronic Obstructive Pulmonary Disease (COPD) and comorbidities: the COPE-III study protocol.
Lenferink A; Frith P; van der Valk P; Buckman J; Sladek R; Cafarella P; van der Palen J; Effing T
Contemp Clin Trials; 2013 Sep; 36(1):81-9. PubMed ID: 23770110
[TBL] [Abstract][Full Text] [Related]
52. Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review.
Ghoorah K; De Soyza A; Kunadian V
Cardiol Rev; 2013; 21(4):196-202. PubMed ID: 23095685
[TBL] [Abstract][Full Text] [Related]
53. Lung cancer - a comorbidity in chronic obstructive pulmonary disease.
Roca M; Roca IC; Mihăescu T
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1055-62. PubMed ID: 23700888
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of the oxidant and antioxidant balance in the pathogenesis of chronic obstructive pulmonary disease.
Cristóvão C; Cristóvão L; Nogueira F; Bicho M
Rev Port Pneumol; 2013; 19(2):70-5. PubMed ID: 23199890
[TBL] [Abstract][Full Text] [Related]
55. Animal models of chronic obstructive pulmonary disease.
Fricker M; Deane A; Hansbro PM
Expert Opin Drug Discov; 2014 Jun; 9(6):629-45. PubMed ID: 24754714
[TBL] [Abstract][Full Text] [Related]
56. Oxidants/antioxidants and COPD.
MacNee W
Chest; 2000 May; 117(5 Suppl 1):303S-17S. PubMed ID: 10843965
[TBL] [Abstract][Full Text] [Related]
57. Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies.
Chan SMH; Selemidis S; Bozinovski S; Vlahos R
Pharmacol Ther; 2019 Jun; 198():160-188. PubMed ID: 30822464
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
59. The mechanisms of cachexia underlying muscle dysfunction in COPD.
Remels AH; Gosker HR; Langen RC; Schols AM
J Appl Physiol (1985); 2013 May; 114(9):1253-62. PubMed ID: 23019314
[TBL] [Abstract][Full Text] [Related]
60. Mortality in COPD: Role of comorbidities.
Sin DD; Anthonisen NR; Soriano JB; Agusti AG
Eur Respir J; 2006 Dec; 28(6):1245-57. PubMed ID: 17138679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
